Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydrotalcite is an antacid used to treat heartburn, dyspepsia (indigestion), gastroesophageal reflux disease, gastritis, and peptic ulcers. It is a layered double hydroxide compound composed of aluminum and magnesium that neutralizes gastric acid upon contact in the stomach[1][2][3][5]. Its mechanism of action involves direct acid neutralization as well as promoting gastric mucosal protection and healing by increasing prostaglandin E2 (PGE2) levels, activating epidermal growth factor (EGF), and counteracting cyclooxygenase (COX) inhibition caused by NSAIDs[6]. Hydrotalcite is approved for use in several countries for the relief of symptoms associated with excess gastric acidity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrotalcite.